Federation Des Caisses Desjardins Du Quebec Concert Pharmaceuticals, Inc. Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Aug 30, 2024	SELL	$5.88 - $12.35 $42,953 - $90,216	-7,305 Closed	0 $0
Q2 2019 Aug 30, 2024	SELL	$9.44 - $13.12 $213,268 - $296,407	-22,592 Reduced 75.57%	7,305 $87.5 Million
Q4 2018 Aug 30, 2024	BUY	$11.25 - $16.17 $336,341 - $483,434	29,897 New	29,897 $376 Million
Q1 2018 Aug 30, 2024	BUY	$19.24 - $28.03 $375,006 - $546,332	19,491 Added 77.36%	44,685 $1.02 Billion
Q4 2017 Aug 30, 2024	BUY	$13.96 - $29.05 $351,708 - $731,885	25,194	25,194 $650 Million

Others Institutions Holding CNCE

# of Institutions

Shares Held

Call Options Held

Put Options Held

Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

View Full List

About CONCERT PHARMACEUTICALS, INC.

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

More about CNCE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account